Ruxolitinib (phosphate)
Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.
Product Specifications
CAS Number
[1092939-17-7]
Product Name Alternative
INCB018424 phosphate
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; JAK; Mitophagy
Type
Reference compound
Related Pathways
Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Ruxolitinib-phosphate.html
Purity
99.97
Solubility
DMSO : 220 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic)
Smiles
N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
Molecular Formula
C17H21N6O4P
Molecular Weight
404.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115 (15), 3109-3117.|[2]Fleischman AG, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Nov 21;122 (22) :3628-31.|[3]de Bock CE, et al. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018 May;8 (5) :616-631.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
JAK1; JAK2; JAK3; Tyk2
Citation 01
Adv Funct Mater. 2025 Apr 21.|bioRxiv. 2025 Oct 22.|Blood. 2013 Nov 21;122 (22) :3628-31.|Cancer Discov. 2018 May;8 (5) :616-631.|EMBO Mol Med. 2025 Aug;17 (8) :2040-2070.|Haematologica. 2020 Jan;105 (1) :124-135. |Harvard Medical School LINCS LIBRARY|Inflamm Res. 2015 Jan;64 (1) :41-51. |Int J Biol Macromol. 2022 Jan 1:194:153-162.|J Hematol Oncol. 2021 Jun 24;14 (1) :97.|N Engl J Med. 2024 May 30;390 (20) :1873-1884.|Neuroscience. 2019 Dec 1;422:12-20.|Oncotarget. 2017 Oct 4;8 (55) :94040-94053. |Patent. US20250228857A1.|ACS Chem Biol. 2017 May 19;12 (5) :1245-1256.|Acta Pharmacol Sin. 2021 May;42 (5) :814-823.|Adv Funct Mater. 2025 Apr 21.|Adv Healthc Mater. 2025 Jul 22:e01838.|Adv Sci (Weinh) . 2021 Jan 6;8 (5) :2002738.|AIDS. 2016 Aug 24;30 (13) :2053-64. |Anim Reprod Sci. 2025 Apr 28:277:107850.|Ann Rheum Dis. 2025 Sep 25:S0003-4967 (25) 04383-3.|Biochem Biophys Res Commun. 2020 May 7;525 (3) :662-667.|Biochem Pharmacol. 2020 Aug;178:114103.|Biochem Pharmacol. 2025 Jun 24:117088.|Biochim Biophys Acta Mol Basis Dis. 2025 Sep 18;1872 (1) :168056.|Biomed Pharmacother. 2023 Aug:164:114902.|Biomedicines. 2022 Apr 18;10 (4) :928. |bioRxiv. 2021 Feb 5.|bioRxiv. 2023 May 22:2023.05.22.541644.|bioRxiv. 2024 Aug 8:2024.08.06.606693.|bioRxiv. 2024 Dec 3:2024.11.27.625710.|bioRxiv. 2025 Aug 21:2025.08.15.670603.|bioRxiv. 2025 February 21.|bioRxiv. 2025 January 31.|bioRxiv. 2025 Jul 8:2025.07.04.663209.|bioRxiv. 2025 Jun 3:2025.06.02.657064.|bioRxiv. 2025 June 03.|bioRxiv. 2025 Mar 17:2025.03.14.643359.|bioRxiv. 2025 Nov 20.|bioRxiv. 2025 Oct 22.|bioRxiv. 2025 Sep 21.|Blood Adv. 2025 Aug 19:bloodadvances.2025016898.|Blood Adv. 2025 Jul 2:bloodadvances.2024015322.|blood advances. 2018 Dec 11;2 (23) :3428-3442.|Blood Sci. 2023 Jul 12;5 (4) :258-268.|Blood. 2014 Dec 18;124 (26) :3924-31.|Cancer Biol Ther. 2023 Dec 31;24 (1) :2269637.|Cancer Cell Int. 2015 Mar 12:15:30.|Cancer Commun (Lond) . 2021 Dec;41 (12) :1354-1372.|Cancer Discov. 2024 Oct 4;14 (10) :1964-1989.|Cancer Immunol Res. 2025 Jan 9:OF1-OF19.|Cancer Res. 2023 Jan 18;83 (2) :264-284.|Cancer Sci. 2021 Mar;112 (3) :997-1010.|Cancers (Basel) . 2022 Dec 31;15 (1) :296.|Cancers (Basel) . 2024 Apr 16, 16 (8), 1511.|Cancers (Basel) . 2024 Apr 16;16 (8) :1511.|Cell Biosci. 2021 Aug 4;11 (1) :156.|Cell Cycle. 2020 Aug;19 (16) :2074-2080.|Cell Death Dis. 2020 Nov 15;11 (11) :982.|Cell Death Dis. 2022 May 25;13 (5) :496.|Cell Death Dis. 2025 Jan 26;16 (1) :46.|Cell Death Discov. 2025 Oct 24;11 (1) :483.|Cell Mol Biol Lett. 2024 Feb 2;29 (1) :22.|Cell Mol Gastroenterol Hepatol. 2024;17 (2) :219-235.|Cell Mol Immunol. 2022 Nov;19 (11) :1263-1278.|Cell Mol Immunol. 2022 Oct;19 (10) :1130-1140.|Cell Rep Med. 2024 Dec 3:101849.|Cell Rep Med. 2024 Mar 19;5 (3) :101472.|Cell Rep. 2020 Sep 15;32 (11) :108158.|Cell Rep. 2023 Mar 30;42 (4) :112327.|Cell Rep. 2024 Apr 23;43 (4) :114111.|Cell Rep. 2024 Oct 11;43 (10) :114866.|Cell Rep. 2025 Oct 29;44 (11) :116480.|Cell Signal. 2025 Jul:131:111706.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell. 2021 Apr 15;184 (8) :2167-2182.e22.|Cell. 2024 Apr 25;187 (9) :2288-2304.e27.|Chemosphere. 2021 Jan;263:127849.|Clin Cancer Res. 2018 Apr 15;24 (8) :1917-1931.|Clin Cosmet Investig Dermatol. 2025 Apr 24:18:999-1009.|Clin Exp Dermatol. 2021 Jul;46 (5) :880-887.|Clin Exp Immunol. 2021 Nov 27;207 (1) :113-122.|Clin Exp Immunol. 2022 Jan 28;207 (1) :113-122.|Columbia University. 2024.|Cytojournal. 2024 Dec 20:21:69.|Dev Cell. 2025 Aug 25:S1534-5807 (25) 00499-X.|EMBO Mol Med. 2025 Oct 30.|Emerg Microbes Infect. 2023 Dec;12 (1) :2178238.|Endocr Relat Cancer. 2023 Jul 25;30 (9) :e230130.|Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Eur J Haematol. 2023 Apr;110 (4) :435-443.|Eur J Pharmacol. 2022 Apr 5:920:174822.|Exp Dermatol. 2025 Jul;34 (7) :e70132.|Exp Eye Res. 2021 Jan;202:108375.|Exp Hematol. 2022 May:109:55-67.e2.|FASEB J. 2025 Sep 30;39 (18) :e71032.|FEBS J. 2022 Apr;289 (7) :1968-1983.|Free Radic Biol Med. 2025 Nov:239:91-103.|Front Oncol. 2021 Aug 6:11:629350.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Gut. 2020 Jan;69 (1) :122-132. |Harvard Medical School. June 13, 2018|Harvard University. 2024 May.|Hemasphere. 2021 Aug 11;5 (9) :e630.|Inflammation. 2025 Jan 13.|Int Immunopharmacol. 2023 Mar:116:109723.|Int Immunopharmacol. 2024 Dec 25:146:113817.|Int Immunopharmacol. 2025 Jan 17:148:113972.|Int Immunopharmacol. 2025 Oct 30:164:115351.|Int J Biol Macromol. 2025 Jan 17:298:140025.|Int J Clin Exp Pathol. 2017;10 (3) :3033-3042.|Int J Med Microbiol. 2020 Oct;310 (7) :151450.|Int J Mol Sci. 2022 Apr 12;23 (8) :4277.|Int J Mol Sci. 2022 Dec 9;23 (24) :15646.|Int J Mol Sci. 2022 May; 23 (9) : 5156.|Int J Mol Sci. 2023 Apr 13;24 (8) :7219.|Int J Mol Sci. 2023 May 25;24 (11) :9243.|Int J Mol Sci. 2025 Jun 26;26 (13) :6123.|Int J Oral Sci. 2025 Mar 19;17 (1) :22.|Invest New Drugs. 2022 Dec;40 (6) :1194-1205.|iScience. 2021 Sep 25;24 (10) :103173.|iScience. 2024 May 16.|J Adv Res. 2023 May:47:151-162.|J Agric Food Chem. 2015 Apr 8;63 (13) :3472-80. |J Biol Chem. 2015 Nov 27;290 (48) :29022-34. |J Biotechnol. 2025 Mar:399:9-18.|J Cell Mol Med. 2021 Jan;25 (2) :1089-1099.|J Cell Mol Med. 2022 Jul;26 (14) :3902-3912.|J Cell Mol Med. 2025 Jul;29 (14) :e70720.|J Clin Invest. 2021 Dec 15;131 (24) :e145501.|J Exp Clin Cancer Res. 2025 Jun 5;44 (1) :172.|J Exp Med. 2024 Jul 1;221 (7) :e20240111.|J Exp Med. 2024 Mar 4;221 (3) :e20230683.|J Exp Med. 2024 Mar 4;221 (3) :e20232028.|J Immunother Cancer. 2025 May 11;13 (5) :e010831.|J Inflamm Res. 2025 Oct 9:18:14075-14096.|J Leukoc Biol. 2022 Nov;112 (5) :1343-1356.|J Leukoc Biol. 2025 Dec 1;117 (12) :qiaf157.|J Med Virol. 2023 Nov;95 (11) :e29230.|J Mol Histol. 2025 Nov 24;57 (1) :4.|J Pharmacol Exp Ther. 2025 Oct 31;393 (1) :103767.|J Physiol Investig. 2025 Mar 1;68 (2) :109-119.|J Vet Sci. 2021 May;22 (3) :e39.|J Virol. 2024 Jun 28:e0073824.|J Virol. 2025 Aug 18:e0113025.|J Virol. 2025 Jun 17;99 (6) :e0046925.|JCI Insight. 2018 Sep 6;3 (17) . pii: 120750.|JCI Insight. 2024 Oct 29:e173665.|JCI Insight. 2025 Jul 8;10 (13) :e188843.|Kaohsiung J Med Sci. 2023 Jan;39 (1) :26-39.|Leuk Lymphoma. 2023 Jan;64 (1) :71-78.|Leukemia. 2012 Oct;26 (10) :2233-44.|Leukemia. 2023 May;37 (5) :1068-1079.|Metab Brain Dis. 2023 Mar;38 (3) :945-960.|Metab Brain Dis. 2025 Oct 30;40 (8) :301.|Mol Biol Rep. 2023 Jan;50 (1) :319-329.|Mol Biol Rep. 2024 Jul 22;51 (1) :832.|Mol Biomed. 2025 Apr 8;6 (1) :21.|Mol Cell Biochem. 2025 Apr;480 (4) :2645-2660.|Mol Genet Genomics. 2025 Feb 22;300 (1) :23.|Mol Med. 2025 May 13;31 (1) :184.|Mol Ther Nucleic Acids. 2025 Mar 5;36 (2) :102502. |Nat Biomed Eng. 2025 Oct 22.|Nat Cancer. 2022 Sep;3 (9) :1071-1087.|Nat Cancer. 2025 Sep;6 (9) :1537-1558.|Nat Cell Biol. 2025 Nov 17.|Nat Chem Biol. 2025 Apr 25.|Nat Commun. 2021 Aug 13;12 (1) :4917.|Nat Commun. 2023 Apr 24;14 (1) :2342.|Nat Commun. 2023 May 10;14 (1) :2685.|Nat Commun. 2024 Aug 26;15 (1) :7165.|Nat Commun. 2024 Aug 6;15 (1) :6685.|Nat Commun. 2024 Jan 10;15 (1) :446.|Nat Commun. 2025 Aug 4;16 (1) :7134.|Nat Commun. 2025 Jul 29;16 (1) :6972.|Nat Commun. 2025 Jul 8;16 (1) :6270.|Nat Commun. 2025 Nov 20;16 (1) :10222.|Nat Commun. 2025 Sep 29;16 (1) :8560.|Nat Med. 2018 Aug;24 (8) :1143-1150. |Nature. 2022 Sep;609 (7928) :785-792.|Nature. 2023 Mar;615 (7950) :158-167.|Nature. 2025 Jan;637 (8046) :726-735. |Neuroscience Research Notes. 2025 Feb 02.|Neurotoxicology. 2024 Aug 27:S0161-813X (24) 00100-1.|Nutrients. 2019 Apr 5;11 (4) :791.|Oncogenesis. 2019 Feb 22;8 (3) :15. |Oncol Rep. 2018 Aug;40 (2) :635-646. |Oncol Rep. 2024 May;51 (5) :71.|Oncol Rep. 2025 Mar;53 (3) :40.|Patent. US20180263995A1.|Patent. US20210025893A1.|Patent. US20220305048A1.|Pennsylvania State University. 2025.|PLoS Biol. 2023 Mar 17;21 (3) :e3002039.|PLoS Genet. 2024 May 28;20 (5) :e1011293.|PLoS One. 2017 Jun 30;12 (6) :e0180244.|PLoS One. 2021 Sep 30;16 (9) :e0258140.|PLoS One. 2022 Oct 14;17 (10) :e0276010.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|PLoS Pathog. 2025 Oct 27;21 (10) :e1013623.|Poultry Sci. 2021 May;100 (5) :101085.|Preprints. 2025 May 08.|Proc Natl Acad Sci U S A. 2022 Apr 12;119 (15) :e2122512119.|Proc Natl Acad Sci U S A. 2024 Nov 5;121 (45) :e2412725121.|Res Sq. 2024 Jun 13.|Res Sq. 2025 Apr 14.|Res Sq. 2025 Sep 25.|Research Square Preprint. 2023 Sep 11.|Research Square Print. August 22nd, 2022.|Ruperto Carola University Heidelberg. 2023 Jun 1.|Sci Adv. 2024 Aug 9;10 (32) :eadn9519.|Sci Adv. 2024 Mar 22;10 (12) :eadl0368.|Sci Immunol. 2024 Jul 12;9 (97) :eadn0178.|Sci Rep. 2021 Feb 15;11 (1) :3847.|Sci Rep. 2024 Oct 10;14 (1) :23725.|Sci Rep. 2025 May 15;15 (1) :16869.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Sci Transl Med. 2022 Aug 10;14 (657) :eabg3277.|Signal Transduct Target Ther. 2024 Mar 9;9 (1) :65.|SSRN. 2025 Feb 11.|SSRN. 2025 Jul 26.|Talanta. 2020 Feb 1;208:120450.|Theranostics. 2022 Oct 3;12 (16) :7051-7066.|Université de Lausanne. 2024 Feb 7.|University of Düsseldorf. 2024.|University of Michigan. Cellular and Molecular Biology. 2022 Aug.|University of Pennsylvania. 2025.|University of Washington. 2025.|University of Zürich. Department of Dermatology. 2021 Dec.|Vet Microbiol. 2022 Dec:275:109594.|Vet Microbiol. 2025 Apr:303:110444.|View. 2025 Oct 28.|Virology. 2024 Sep 14:600:110245.|Virology. 2025 May 13:609:110574.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6322574-01 0.2 mL
MST1, CT (MST1, D3F15S2, DNF15S2, HGFL, Hepatocyte growth factor-like protein, Macrophage stimulatory protein, Macrophage-stimulating protein, Hepatocyte growth factor-like protein alpha chain, Hepatocyte growth factor-like protein beta chain) (FITC)
Ask
View Details 
MBS6322574-02 5x 0.2 mL
MST1, CT (MST1, D3F15S2, DNF15S2, HGFL, Hepatocyte growth factor-like protein, Macrophage stimulatory protein, Macrophage-stimulating protein, Hepatocyte growth factor-like protein alpha chain, Hepatocyte growth factor-like protein beta chain) (FITC)
Ask
View Details 